Biomea Fusion (BMEA) vs Cingulate (CING)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Cingulate (CING) has outperformed Biomea Fusion (BMEA) over the past year, gaining 17.8% versus a loss of 42.5%. Cingulate is the larger company by market cap ($63.4 million vs $62.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMEA | CING |
|---|---|---|
| Share price | $0.8689 | $4.36 |
| Market cap | $62.82M | $63.40M |
| 1-day change | +3.89% | -0.68% |
| YTD return | -29.93% | +0.46% |
| 1-year return | -42.46% | +17.84% |
| 5-year return | -92.09% | — |
| EPS (TTM) | $-0.29 | $-3.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-61.80M | $-22.45M |
| 52-week high | $2.24 | $11.89 |
| 52-week low | $0.7995 | $3.16 |
| Distance from 52-week high | -61.16% | -63.33% |
| Analyst consensus | buy | none |
| Avg. price target upside | +705.62% | +386.24% |
| Average volume | 1.93M | 122.39K |
| Shares outstanding | 72.30M | 14.54M |
| Employees | 37 | 14 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CING has outperformed BMEA by 60.3 percentage points over the past year.
About Biomea Fusion
BMEA stock →Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees
About Cingulate
CING stock →Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
BMEA vs CING FAQ
Which is bigger, Biomea Fusion or Cingulate?
Cingulate (CING) is larger, with a market capitalization of $63.40M compared with $62.82M for Biomea Fusion (BMEA).
Which stock has performed better over the past year, BMEA or CING?
CING returned +17.84% over the past 12 months, compared with -42.46% for BMEA (price return, excluding dividends). Past performance does not predict future results.
Are Biomea Fusion and Cingulate in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.